Summary
The ABACUS trial, published in Nature Medicine in 2019, investigated neoadjuvant atezolizumab in operable urothelial carcinoma, combining clinical efficacy assessment with detailed biomarker profiling to identify predictors of response. The study measured pathological response rates alongside immune and genomic markers to characterise which patients benefit most from this immunotherapeutic approach. As a cancer immunology study, this work sits outside Vitagri's core remit in farming, soil health, and food-system nutrition.
UK applicability
This clinical oncology trial has no direct applicability to UK farming systems, soil health, or food-system research. It may inform UK cancer treatment guidelines but does not address agricultural or nutritional outcomes within Vitagri's scope.
Key measures
Pathological complete response (pCR) rate, major pathological response (MPR), PD-L1 expression, tumour mutational burden, T-cell infiltration, and genomic signatures
Outcomes reported
The study evaluated clinical efficacy and biomarker responses to neoadjuvant atezolizumab (a PD-L1 inhibitor) in patients with operable urothelial carcinoma, measuring pathological complete response rates and associated immune and genomic biomarkers.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.